

**DRUG NAME: Dexrazoxane****SYNONYM(S):** ICRF-187**COMMON TRADE NAME(S):** ZINECARD<sup>®</sup>, CARDIOXANE<sup>®</sup>**CLASSIFICATION:** Cytoprotectant*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.***MECHANISM OF ACTION:**

Dexrazoxane is a cyclic derivative of edetic acid (EDTA) that readily penetrates cell membranes. Dexrazoxane is converted intracellularly to a ring-opened chelating agent. The hydrolysis products of dexrazoxane are thought to exert their effects by chelating free or bound intracellular iron in the myocardium, thus preventing the formation of the anthracycline-iron complex and resultant free radical generation.<sup>1,2</sup> The hydrolysis products are believed to be responsible for most of the activity of dexrazoxane.<sup>3</sup>

**PHARMACOKINETICS:**

Interpatient variability	no information found	
Distribution	highest concentrations found in the liver and kidneys	
	cross blood brain barrier?	no
	volume of distribution	29-90 L
	plasma protein binding	< 2%
Metabolism	hydrolyzed by dihydropyrimidine aminohydrolase (DHPase) in the liver and kidney, and dihydroorotase (DHOase) in the heart, liver, kidney, erythrocytes and leukocytes	
	active metabolite(s)	yes
	inactive metabolite(s)	no information found
Excretion	predominantly renal (unchanged)	
	urine	42-48%
	feces	no information found
	terminal half life	2-4 h
	clearance	13.8 L/h (0.29 L/h/kg)
Gender	clearance: not clinically significant	
Elderly	no information found	
Children	volume of distribution: 0.96 L/kg clearance: 0.36 L/h/kg	
Ethnicity	no information found	

Adapted from standard references<sup>3,4</sup> unless specified otherwise.**USES:****Primary uses:**\*Cardioprotectant against doxorubicin-induced cardiotoxicity<sup>1</sup>**Other uses:**Currently being studied in children<sup>5</sup>

\*Health Canada approved indication

**SPECIAL PRECAUTIONS:**

**Contraindications:** Should not be used as a chemotherapeutic agent<sup>1</sup> or with chemotherapy regimens that do not contain doxorubicin.<sup>6</sup>

**Carcinogenicity:** Secondary malignancies (acute myeloid leukemia, T-cell lymphoma, B-cell lymphoma, cutaneous basal cell or squamous cell carcinoma) have been reported in patients treated chronically with oral razoxane, a racemic mixture containing dexrazoxane as the S(+)-enantiomer.<sup>6,7</sup>

**Mutagenicity:** Not mutagenic in Ames test. Dexrazoxane is clastogenic in mammalian *in vitro* and *in vivo* chromosome tests.<sup>6,7</sup>

**Fertility:** Animal studies have shown impaired fertility at maturity in both males and females at a dose of 8 mg/kg.<sup>7</sup>

**Pregnancy:** FDA Pregnancy Category C.<sup>7</sup> Animal studies have shown fetal risks and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the fetus.

**Breastfeeding** is not recommended due to the potential secretion into breast milk.<sup>1,7</sup>

**SIDE EFFECTS:**

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.

**Determination of the effect of dexrazoxane alone on patient tolerability is difficult given the morbidity in this patient population and the effect of concurrently administered anthracyclines and other chemotherapeutic agents. The only adverse event that was observed in 5% more patients on FAC + dexrazoxane than on FAC + placebo was pain on injection.<sup>2</sup>**

ORGAN SITE	SIDE EFFECT
blood/bone marrow/ febrile neutropenia	granulocytopenia (severe 88%)*
	thrombocytopenia (severe 10%)*
cardiovascular (general)	congestive heart failure (1%)*
	phlebitis (5%)*
constitutional symptoms	fatigue/malaise (62%)*
	fever (35%)*
dermatology/skin	<i>extravasation hazard: none</i>
	alopecia (94%)*
	erythema/streaking (7%)*
	recall skin reaction (1%)*
	urticaria (4%)*
gastrointestinal	<i>emetogenic potential: high moderate*</i>
	anorexia (50%)*
	diarrhea (22%)*
	dysphagia (6%)*

ORGAN SITE	SIDE EFFECT
	esophagitis (5%)*
	nausea (82%)*
	stomatitis (36%)*
	vomiting (63%)*
hemorrhage	hemorrhage (2%)*
infection	infection and/or sepsis (31%)*
neurology	neurotoxicity (16%)*
pain	<b><i>pain on injection (11%)</i></b>

Adapted from standard reference<sup>1</sup> unless specified otherwise.

**\*Adverse events and incidences were those reported for dexrazoxane when given with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC regimen) and likely attributable to the FAC regimen itself.**

#### INTERACTIONS:

AGENT	EFFECT	MECHANISM	MANAGEMENT
dexrazoxane + combination of 5-FU, doxorubicin and cyclophosphamide	may experience more severe leucopenia, granulocytopenia and thrombocytopenia at nadir, but no significant effect on recovery time <sup>7</sup>	unknown	none (clinically non-significant) <sup>8</sup>

#### SUPPLY AND STORAGE:

***For basic information on the current brand used at the BC Cancer Agency, see [Chemotherapy Preparation and Stability Chart in Appendix](#).***

***Injection:*** Pfizer Canada Inc. supplies dexrazoxane as 250 mg and 500 mg single dose vials of sterile lyophilized powder. Diluent is not provided. Store at room temperature.<sup>9</sup>

#### SOLUTION PREPARATION AND COMPATIBILITY:

***For basic information on the current brand used at the BC Cancer Agency, see [Chemotherapy Preparation and Stability Chart in Appendix](#).***

***Compatibility:*** consult detailed reference

#### PARENTERAL ADMINISTRATION:

BCCA administration guideline noted in ***bold, italics***

Subcutaneous	no information found
Intramuscular	no information found
<b><i>Direct intravenous</i></b>	<b><i>for cardioprotection, slow IV push, 30 min before to 15 min after the start of doxorubicin<sup>1,6</sup></i></b>

BCCA administration guideline noted in ***bold, italics***

<b><i>Intermittent infusion</i></b>	<b><i>for cardioprotection, rapid IV drip from an empty bag (e.g., VIAFLEX<sup>®</sup>) 30 min before to 15 min after the start of doxorubicin<sup>1,6</sup></i></b>
Continuous infusion	no information found
Intraperitoneal	no information found
Intrapleural	no information found
Intrathecal	no information found
Intra-arterial	no information found
Intravesical	no information found

## DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or with other toxicities.

### **Adults:**

BCCA usual dose noted in ***bold, italics***

<i>Intravenous:</i>	Cycle Length: with each dose of doxorubicin	500 mg/m <sup>2</sup> IV for one dose on day 1 <sup>1,6</sup>
<i>Concurrent radiation:</i>	no information found	
<i>Dosage in myelosuppression:</i>	modify according to protocol by which patient is being treated; if no guidelines available, refer to Appendix 6 "Dosage Modification for Myelosuppression"	
<i>Dosage in renal failure:</i>	reduce dose by 50% in patients with creatinine clearance < 40 mL/min <sup>10</sup>	
<i>Dosage in hepatic failure:</i>	proportionate to doxorubicin dose reduction (10:1 ratio of dexrazoxane:doxorubicin is recommended) <sup>1,6</sup>	
<i>Dosage in dialysis</i>	possibly dialyzable <sup>1,6</sup>	

### **Children:**

<i>Intravenous:</i>	10:1 ratio of dexrazoxane:doxorubicin IV prior to each dose of doxorubicin (COG AOST0121 for osteosarcoma) <sup>5</sup>
---------------------	---

## REFERENCES:

1. Repchinsky C editor. Compendium of Pharmaceuticals and Specialties. Ottawa, Ontario: Canadian Pharmacists Association; 2004.

2. McEvoy G. 2005 AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2005.
3. Wiseman LR, Spencer CM. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. *Drugs* 1998;56(3):385-403.
4. Cvetkovic RS, Scott LJ. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy. *Drugs* 2005;65(7):1005-24.
5. Roberta Esau. Personal Communication. Pharmacist BC Children's Hospital & Sunny Hill Health Centre for Children; 4 July 2005.
6. Pfizer Canada Inc. Zinecard product monograph. Kirkland, Quebec; 8 October 2003.
7. Pharmacia & Upjohn Company. ZINECARD® product monograph. Kalamazoo, Michigan; August 1998.
8. Karen Gelmon MD. Personal Communication. BC Cancer Agency Breast Tumor Group; 25 July 2005.
9. Pfizer Canada Inc. ZINECARD® product monograph. Kirkland, Quebec; 12 August 2010.
10. Pfizer Inc. ZINECARD® product monograph. New York, New York; December 2005.